Shire Hits Sandoz With 2nd Suit Over Generic Intuniv

Law360, New York (January 9, 2012, 6:48 PM EST) -- Drugmaker Shire LLC on Monday hit rival Sandoz Inc. with a second patent suit in Colorado federal court over Sandoz’s proposal to manufacture a generic version of the attention deficit hyperactivity disorder drug Intuniv.

Shire filed the lawsuit after Sandoz, the generic-pharmaceuticals division of Novartis AG, amended its application to make the generic version to include 1-milligram, 2-milligram and 3-milligram dosages. Sandoz's original application was for a 4-milligram dose.

Dublin-based Shire claims Sandoz's generic version, in any dosage, would violate three Intuniv patents.

Shire says it...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.